The blistering diseases

Med Clin North Am. 1998 Nov;82(6):1239-83. doi: 10.1016/s0025-7125(05)70415-6.

Abstract

The intent and purpose of the authors is to familiarize the reader with the principles that govern the diagnosis and management of autoimmune mucocutaneous blistering diseases. The purpose was not to be all-inclusive but illustrative. There are several other blistering diseases that have not been discussed because of the limited scope of this article. Of these, toxic epidermal necrolysis, erythema multiforme, and the like warrant the same attention and early recognition. These are covered in different articles. For the same reasons, certain genetically linked blistering diseases have not been discussed.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases / diagnosis*
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / physiopathology
  • Child
  • Dermatitis Herpetiformis / diagnosis
  • Dermatitis Herpetiformis / drug therapy
  • Diagnosis, Differential
  • Epidermolysis Bullosa Acquisita / diagnosis
  • Epidermolysis Bullosa Acquisita / drug therapy
  • Female
  • Humans
  • Immunoglobulin A / analysis
  • Lupus Erythematosus, Systemic / diagnosis
  • Lupus Erythematosus, Systemic / drug therapy
  • Pemphigoid Gestationis / diagnosis
  • Pemphigoid Gestationis / drug therapy
  • Pemphigoid, Benign Mucous Membrane / diagnosis
  • Pemphigoid, Benign Mucous Membrane / drug therapy
  • Pemphigoid, Bullous / diagnosis
  • Pemphigoid, Bullous / drug therapy
  • Pemphigus / classification
  • Pemphigus / diagnosis
  • Pemphigus / drug therapy
  • Pregnancy
  • Prognosis
  • Skin Diseases, Vesiculobullous / diagnosis
  • Skin Diseases, Vesiculobullous / drug therapy
  • Skin Diseases, Vesiculobullous / immunology*
  • Skin Diseases, Vesiculobullous / physiopathology

Substances

  • Immunoglobulin A